GSK, Shionogi's dolutegravir proves equal to Isentress in head-to-head HIV study; GSK ups stakes in Theravance with $213M investment;

@FierceBiotech: New drug blocks brain cancer advance, making chemo kill easier. Article | Follow @FierceBiotech

@JohnCFierce: So do we add Tokai's CRPC drug galeterone to the list of promising early-stage treatments? Story | Follow @JohnCFierce

@RyanMFierce: Social and/or collaboration apps are changing how we work in media, and at biotech companies, too. Item | Follow @RyanMFierce

> Investigators for GSK ($GSK) and Shionogi say that their once-daily HIV drug dolutegravir is equally as effective as Merck's ($MRK) twice-daily Isentress. Dolutegravir slightly edged Isentress's results in the late-stage study. GSK is hoping to make a comeback in the field with this new drug. Report

> Underscoring its commitment to Relovair, the follow-up treatment to Advair, GlaxoSmithKline ($GSK) says it will invest an additional $213 million in Theravance ($THRX), boosting its stake to 26.8%. Story

> Novo Nordisk ($NVO) plans to push ahead on the development of a once-weekly diabetes treatment to help fend off competition from Amylin's ($AMLN) Bydureon. Report

> Sources tell SonntagsZeitung that Roche ($RHHBY) may walk away from its bid for Illumina ($ILMN), adding that Roche won't raise its offer a second time. It may be no coincidence that both these points are likely to reflect Roche's strategy in its attempted acquisition of Illumina. Story

Pharma News

@FiercePharma: Now FDA-approved, Ranbaxy plant in India ships copycat Lipitor--Reuters. News | Follow @FiercePharma

> Hikma to plow $300M into M&A, internal growth. Article

> Rare-disease drugs won't help out-of-work pharma reps. More

Medical Devices News

@FierceMedDev: Therapeutic hypothermia startup raises $1M, looks to clinical studies--MedCity News. Story | Follow @FierceMedDev

> Device tax creeps into presidential, Senate campaigns. Article

> Medtronic will pay $85M to resolve Infuse shareholder suit. News

> 2 molecular diagnostics companies grab major money. Story

> Swiss report: Roche may abandon Illumina bid. More

IT News

> NIH grabs share of Obama's new $200M bet on big data. News

> Computer-based discovery biotech from Israel lands in Bay Area. Story

> Tech startup cuts through social media noise for drug and device outfits. More

> Computer-based discovery biotech from Israel lands in Bay Area. Article

> Big Pharma and devicemakers plot careful social media moves. Piece

And Finally… A new study found that vitamin D had a noticeable impact on a biomarker for prostate cancer, indicating its potential for helping treat the ailment. Release

 

Suggested Articles

AbbVie snagged the option to license Harpoon’s anti-BCMA multiple myeloma candidate and the duo added up to six new targets to their discovery deal.

In this week's EuroBiotech Report, Bayer's heart failure drug clears phase 3 test, ABPI calls for more U.K. investment and GHO raises €975 million. 

In our EuroBiotech roundup this week, Azeria raises £32 million, Zealand delays phase 3 readout and Galapagos eyes early 2021 IPF futility analysis.